Apollomics Shares Scheduled to Reverse Split on Monday, November 25th (NASDAQ:APLM)

Apollomics, Inc. (NASDAQ:APLM) shares are scheduled to reverse split before the market opens on Monday, November 25th. The 1-100 reverse split was announced on Thursday, November 21st. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, November 22nd.

Apollomics Price Performance

APLM stock traded down $0.05 during midday trading on Thursday, reaching $0.10. The company had a trading volume of 11,199,390 shares, compared to its average volume of 9,109,365. Apollomics has a 1 year low of $0.08 and a 1 year high of $1.23. The firm has a 50-day moving average price of $0.13 and a 200-day moving average price of $0.18.

Hedge Funds Weigh In On Apollomics

An institutional investor recently raised its position in Apollomics stock. Exchange Traded Concepts LLC grew its holdings in Apollomics, Inc. (NASDAQ:APLM) by 247.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,259,117 shares of the company’s stock after buying an additional 896,316 shares during the quarter. Exchange Traded Concepts LLC owned approximately 1.41% of Apollomics worth $179,000 at the end of the most recent quarter. 19.13% of the stock is owned by institutional investors.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.